Methyl((Methylamino)Methyl)Phosphinic Acid

Methyl((Methylamino)Methyl)Phosphinic Acid

SCHEMBL21272008

CCCCCCN.CNCP(C)(=O)O

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 3/20 0.50
GABBR2 O75899 2/20 0.50
GABBR1 Q9UBS5 2/20 0.50
TSHR P16473 2/20 0.50
LPAR2 Q9HBW0 1/20 0.50
CYP1A2 P05177 1/20 0.50
THPO P40225 1/20 0.50
GABRR1 P24046 1/20 0.50
LMNA P02545 1/20 0.48
BLM P54132 1/20 0.48
DNM1 Q05193 8/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 1/20 0.48
EPHX1 P07099 1/20 0.48
S1PR2 O95136 2/20 0.46
S1PR4 O95977 2/20 0.46
S1PR1 P21453 2/20 0.46
S1PR3 Q99500 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21272062 0.84 DNM1 (0.46) GABBR2GABBR1TSHRCYP1A2THPO
SCHEMBL21272099 0.82 S1PR2 (0.47) GABBR2GABBR1TSHRCYP1A2THPO
SCHEMBL21272213 0.82 DNM1 (0.45) GABBR2GABBR1TSHRCYP1A2THPO
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21271995 0.82 DNM1 (0.59) LPAR3GABBR2GABBR1TSHRLPAR2
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21272149 0.82 DNM1 (0.59) LPAR3GABBR2GABBR1TSHRLPAR2
Aminomethyl(Methyl)Phosphinic Acid SCHEMBL21272056 0.82 DNM1 (0.59) LPAR3GABBR2GABBR1TSHRLPAR2
Dodecylamine SCHEMBL6575795 0.82 LPAR3 (0.67) LPAR3GABBR2GABBR1TSHRLPAR2
SCHEMBL21272021 0.82 DNM1 (0.65) LPAR3GABBR2GABBR1TSHRLPAR2
Methyl Phosphonate SCHEMBL8008672 0.82 DNM1 (0.65) LPAR3GABBR2GABBR1TSHRLPAR2
Octadecylamine SCHEMBL28212235 0.82 DNM1 (0.65) LPAR3GABBR2GABBR1TSHRLPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070856-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources SOILGENIC TECH LLC (US) 2026-03-12 US disclosed
US-12497344-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SOILGENIC TECHNOLOGIES, LLC (US) 2025-12-16 US disclosed
US-12139443-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SOILGENIC TECHNOLOGIES, LLC (US) 2024-11-12 US disclosed
US-20220242802-A1 CONCENTRATED LIQUID COMPOSITIONS OF UREASE INHIBITORS FOR NITROGEN SOURCES SOILGENIC TECHNOLOGIES, LLC 2022-08-04 US disclosed
US-20190256437-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources SOILGENIC TECHNOLOGIES, LLC 2019-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497344-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SRM, DNPH1, UROD LPAR3 4861/4885GABBR2 4432/4885GABBR1 4231/4885
US-20260070856-A1 Concentrated Liquid Compositions of Urease Inhibitors for Nitrogen Sources PNP, UMPS, DNPH1 LPAR3 4882/4885GABBR2 3635/4885GABBR1 3523/4885
US-20220242802-A1 CONCENTRATED LIQUID COMPOSITIONS OF UREASE INHIBITORS FOR NITROGEN SOURCES SRM, DNPH1, UROD LPAR3 4861/4885GABBR2 4432/4885GABBR1 4231/4885
US-12139443-B2 Concentrated liquid compositions of urease inhibitors for nitrogen sources SRM, DNPH1, UROD LPAR3 4861/4885GABBR2 4432/4885GABBR1 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.